Myositis Awareness Month sheds light on patient voices, disease costs
Click Here to Manage Email Alerts
Myositis Awareness Month is focused on raising awareness and amplifying voices for patients with diseases falling under the myositis umbrella.
Earlier in May, the Myositis Support and Understanding group launched a social media campaign amplifying voices and raising funds for disease research.
In recognition of Myositis Awareness Month, Healio has compiled five recent stories touching on topics such as medication interruptions in patients with these — and related — diseases and the monetary costs they carry, even before official diagnoses.
Two steps forward, one step back: Hunting for a game-changer in scleroderma
The last 3 years of drug development in scleroderma have come to represent everything that ails the current pipeline for that disease. Read more.
DMARD interruptions rose 80% in early 2021 among autoimmune rheumatic patients
DMARD interruptions in patients with autoimmune rheumatic diseases increased more than 80% between December 2020 and May 2021, leading to higher rates of self-reported flares, according to data published in Arthritis Care & Research. Read more.
‘Pearls and myths’: Oral, cutaneous signs of rheumatic disease hold ‘clue’ to intervention
Managing oral, ocular and cutaneous complications is critical to optimizing outcomes in conditions ranging from Sjögren’s syndrome to juvenile dermatomyositis, according to a presenter who offered a cross-section of “pearls and myths” at ACR Convergence 2021. Read more.
Increased cost of idiopathic inflammatory myopathies begins 2 years before diagnosis
The mean annual direct and indirect costs related to idiopathic inflammatory myopathies are three to five times higher than in the general population, and begin increasing 2 years before diagnosis, according to data from a Swedish registry. Read more.
Immunosuppressants remain ‘cornerstone’ therapy for CTD-ILD as drug options emerge
Although immunosuppressives remain the cornerstone for managing underlying interstitial lung disease in connective tissue diseases, new drug approvals could help shift the treatment paradigm, according to data presented here. Read more.
Reference:
@MyositisSupport. https://twitter.com/MyositisSupport/status/1520765393643741187. May 1, 2022. Accessed May 9, 2022.
Collapse
Healio coverage
Read more about
Click Here to Manage Email Alerts